Multi-Strain Probiotic Mixture Affects Brain Morphology and Resting State Brain Function in Healthy Subjects: An RCT

Cells. 2022 Sep 19;11(18):2922. doi: 10.3390/cells11182922.

Abstract

Probiotics can alter brain function via the gut-brain axis. We investigated the effect of a probiotic mixture containing Bifidobacterium longum, Lactobacillus helveticus and Lactiplantibacillus plantarum. In a randomized, placebo-controlled, double-blinded crossover design, 22 healthy subjects (6 m/16 f; 24.2 ± 3.4 years) underwent four-week intervention periods with probiotics and placebo, separated by a four-week washout period. Voxel-based morphometry indicated that the probiotic intervention affected the gray matter volume of a cluster covering the left supramarginal gyrus and superior parietal lobule (p < 0.0001), two regions that were also among those with an altered resting state functional connectivity. Probiotic intervention resulted in significant (FDR < 0.05) functional connectivity changes between regions within the default mode, salience, frontoparietal as well as the language network and several regions located outside these networks. Psychological symptoms trended towards improvement after probiotic intervention, i.e., the total score of the Hospital Anxiety and Depression Scale (p = 0.056) and its depression sub-score (p = 0.093), as well as sleep patterns (p = 0.058). The probiotic intervention evoked distinct changes in brain morphology and resting state brain function alongside slight improvements of psycho(bio)logical markers of the gut-brain axis. The combination of those parameters may provide new insights into the modes of action by which gut microbiota can affect gut-brain communication and hence brain function.

Trial registration: ClinicalTrials.gov NCT0361565.

Keywords: CO2 inhalation challenge; autonomic nervous system; brain-derived neurotrophic factor (BDNF); cortisol awakening response; gut microbiota; mental health; resting state functional connectivity; serotonin; sleep quality; structural changes.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Bifidobacterium longum*
  • Brain
  • Healthy Volunteers
  • Humans
  • Lactobacillus helveticus*
  • Probiotics* / therapeutic use

Associated data

  • ClinicalTrials.gov/NCT0361565

Grants and funding

Supported by Global Medical Innovation, Pfizer Consumer Healthcare, and the Swedish Knowledge Foundation (funding number: 20150081). On 1 August 2019, Pfizer Consumer Healthcare became part of GSK Consumer Healthcare. The funding sources had no involvement in the conduction of the study.